New PBS behemoth arrives

Posted 6 February 2024 AM

For the first time Vertex has taken first place in the annual top earners list, crushing 2023 with its triple-combination cystic fibrosis drug Trikafta earning a whopping $521.9 million pre-rebate on the R/PBS.

That represents an 80 per cent growth on what it earned for the full year 2022, although it only listed on 1 April of that year after an intense negotiation with the Department of Health.

To see the whole article please log in.

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

Retype password

Not a member? Sign up here